Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Accured Expenses (2016 - 2025)

KalVista Pharmaceuticals' Change in Accured Expenses history spans 10 years, with the latest figure at $8.1 million for Q2 2025.

  • On a quarterly basis, Change in Accured Expenses rose 433.26% to $8.1 million in Q2 2025 year-over-year; TTM through Apr 2025 was $8.9 million, a 178.62% increase, with the full-year FY2025 number at $14.4 million, up 349.64% from a year prior.
  • Change in Accured Expenses hit $8.1 million in Q2 2025 for KalVista Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for KALV hit a ceiling of $8.1 million in Q2 2025 and a floor of -$2.4 million in Q2 2024.
  • Historically, Change in Accured Expenses has averaged $2.1 million across 3 years, with a median of $2.9 million in 2024.
  • Biggest five-year swings in Change in Accured Expenses: crashed 43.23% in 2024 and later surged 433.26% in 2025.
  • Tracing KALV's Change in Accured Expenses over 3 years: stood at $4.0 million in 2023, then rose by 25.49% to $5.0 million in 2024, then soared by 61.11% to $8.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for KALV at $8.1 million in Q2 2025, $5.0 million in Q4 2024, and -$1.8 million in Q3 2024.